Business
AB Science announces issuance of a Canadian patent protecting the composition of matter of AB8939, including its use in the treatment of acute myeloid leukemia, with protection until 2036
PRESS RELEASE AB SCIENCE ANNOUNCES ISSUANCE OF A CANADIAN PATENT PROTECTING THE COMPOSITION OF MATTER OF AB8939, INCLUDING ITS USE IN THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML), WITH PROTECTION UNTIL 2036 THIS PATENT COMPLETES INTELLECTUAL PROPERTY COVERAGE FOR AB8939 ACROSS ALL KEY GEOGRAPHIC AREAS WHERE IT COULD BE MARKETED, INCLUDING EUROPE, USA, CHINA, JAPAN AND SOUTH KOREA, INDIA, ISRAEL, LATIN AMERICA, AND AUSTRALIA Paris, 12 June, 2025, 8am CET AB Science SA (Euronext - FR0010557264 -
About this update from Ab Science Sa
[{"type":"image","alt":"AB Science","displaySize":"","headline":null,"caption":"AB Science","className":"","disableSlideshowImg":false,"size":{"original":{"width":156,"height":160,"url":"https://media.zenfs.com/en/globenewswire.com/7964f89fed41da51df043a8d3708bbe2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/AW2UM4sIueJ.X0XSJNjHhQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTIxNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/7964f89fed41da51df043a8d3708bbe2","width":156,"height":160}},"lazy":false},{"type":"text","content":"PRESS RELEASE","length":13,"tagName":"p"},{"type":"text","content":"AB SCIENCE ANNOUNCES ISSUANCE OF A CANADIAN PATENT PROTECTING THE COMPOSITION OF MATTER OF AB8939, INCLUDING ITS USE IN THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML), WITH PROTECTION UNTIL 2036","length":193,"tagName":"p"},{"type":"text","content":"THIS PATENT COMPLETES INTELLECTUAL PROPERTY COVERAGE FOR AB8939 ACROSS ALL KEY GEOGRAPHIC AREAS WHERE IT COULD BE MARKETED, INCLUDING EUROPE, USA, CHINA, JAPAN AND SOUTH KOREA, INDIA, ISRAEL, LATIN AMERICA, AND AUSTRALIA","length":220,"tagName":"p"},{"type":"text","content":"Paris, 12 June, 2025, 8am CET","length":29,"tagName":"p"},{"type":"text","content":"AB Science SA (Euronext - FR0010557264 - AB) today announced that the patent office of Canada has granted a patent (CA 2975644) protecting the composition of matter of AB8939, and closely related compounds, until 2036. This patent also covers the use of AB8939 in the treatment of hematological disorders and/or proliferative disorders and provides a strong overall protection for the AB8939 clinical development program, including the treatment of acute myeloid leukemia (AML).","length":478,"tagName":"p"},{"type":"text","content":"Issuance of this patent also completes the IP coverage for AB8939 and AML across all key geographic areas where AB8939 could be marketed, including Europe (patent EP 3253749), USA (US 10,570,122), Canada (CA 2975644), China (CN 107531685), South Korea (KR 10-2544132), Japan (JP 6713000), Hong Kong (HK 1243700), Israel (IL 253779), Australia (AU 2016214283), Russia (RU 2758259), Brazil BR (112017016883-9), Mexico (MX 377742), India (IN 480996), and South-Africa (ZA 2017/05537).","length":481,"tagName":"p"},{"type":"text","content":"AB8939 is a novel microtubule destabilizer, currently evaluated in early phase clinical trials for the treatme...